Abstract |
A New Antihypertensive of the Imidazoline Series: 5-Fluoro-2-methyl-imidazolidinylidene-benzamine-monohydrochloride. 5-Fluoro-2-methyl-imidazolidinylidene-benzamine-hydrochloride ( flutonidin, ST 600), a new antihypertensive imidazoline compound, was tested over 3 weeks in 20 patients with moderate to severe hypertension. Blood pressure was significantly lowered in both supine and upright position. In nearly 2/3 of the patients treated normalization of blood pressure was achieved. Side effects like sedation, dry mouth or orthostatic complaints were present in 30%. Toxic effects were not registered. It is recommended to reduce the dosage slowly especially in the aged to prevent, in part severe findings after abrupt withdrawal.
|
Authors | H Brunner, S Djawan, W Dorda, E Penner, G Grabner |
Journal | Arzneimittel-Forschung
(Arzneimittelforschung)
Vol. 27
Issue 8
Pg. 1599-604
( 1977)
ISSN: 0004-4172 [Print] Germany |
Vernacular Title | Ein neues Antihypertensivum der Imidazolinreihe: 5-Fluor-2-methyl-imidazolidinyliden-benzamin-monohydrochlorid (Flutonidin). |
PMID | 334188
(Publication Type: Clinical Trial, English Abstract, Journal Article)
|
Chemical References |
- Antihypertensive Agents
- Imidazoles
- Toluidines
|
Topics |
- Adult
- Aged
- Antihypertensive Agents
(pharmacology, therapeutic use)
- Blood Pressure
(drug effects)
- Clinical Trials as Topic
- Drug Evaluation
- Heart Rate
(drug effects)
- Humans
- Hypertension
(drug therapy)
- Imidazoles
(pharmacology, therapeutic use)
- Middle Aged
- Posture
- Toluidines
(pharmacology, therapeutic use)
|